Search Results - matthias+majetschak

2 Results Sort By:
CCR1 Antagonist for Hemorrhagic Shock Treatment
Advantages Significant reduction in fluid requirements without noticeable adverse events Clinically tested compound for multiple sclerosis, demonstrating favorable safety and tolerability profile Mitigation of inflammation and tissue edema Broad market potential in major surgeries, sepsis, burn care, and military medicine, where fluid management...
Published: 5/11/2026   |   Updated: 8/18/2025   |   Inventor(s): Matthias Majetschak, Xianlong Gao, Elizabeth Cook
Keywords(s): Critical Care / Trauma, Surgery
Category(s): Technology Classifications > Medical > Surgery, Technology Classifications > Medical > Therapeutics
Heteromers Between Chemokine Receptors And Alpha1-Adrenergic Receptors/Vasopressin Receptor 1A As Drug Targets To Modulate Inflammation And Cell Trafficking
­Advantaages: Novel therapeutic opportunities for modulating inflammation and cell trafficking Insights into neuroendocrine control of immune cell behavior Summary: This innovative technology centers around the discovery and characterization of heteromers formed between chemokine receptors (CR) and a1-adrenergic receptors (AR), specifically...
Published: 5/11/2026   |   Updated: 7/31/2023   |   Inventor(s): Matthias Majetschak
Keywords(s): Cancer Treatment, Therapeutics Cell Therapy
Category(s): Technology Classifications > Medical > Biomedical Engineering, Technology Classifications > Medical > Biotechnology, Technology Classifications > Medical > Therapeutics